Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 21.18 crore in September 2023 down 32.85% from Rs. 31.54 crore in September 2022.
Story continues below Advertisement
Quarterly Net Loss at Rs. 86.42 crore in September 2023 down 26.35% from Rs. 68.40 crore in September 2022.
EBITDA stands negative at Rs. 82.98 crore in September 2023 down 32.68% from Rs. 62.54 crore in September 2022.
Sun Pharma Adv shares closed at 241.65 on November 06, 2023 (NSE) and has given 23.64% returns over the last 6 months and -1.65% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Sep'23 | Jun'23 | Sep'22 | | Net Sales/Income from operations | 21.18 | 23.95 | 31.54 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 21.18 | 23.95 | 31.54 | | EXPENDITURE | | Consumption of Raw Materials | 6.47 | 5.17 | 5.58 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 30.71 | 31.12 | 25.32 | | Depreciation | 3.18 | 3.10 | 3.00 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 75.47 | 89.84 | 63.24 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -94.65 | -105.28 | -65.60 | | Other Income | 8.49 | 10.19 | 0.06 | | P/L Before Int., Excpt. Items & Tax | -86.16 | -95.09 | -65.54 | | Interest | 0.26 | 0.26 | 2.86 | | P/L Before Exceptional Items & Tax | -86.42 | -95.35 | -68.40 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -86.42 | -95.35 | -68.40 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -86.42 | -95.35 | -68.40 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -86.42 | -95.35 | -68.40 | | Equity Share Capital | 32.45 | 32.45 | 27.19 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -2.66 | -2.94 | -2.52 | | Diluted EPS | -2.66 | -2.94 | -2.52 | | EPS After Extra Ordinary | | Basic EPS | -2.66 | -2.94 | -2.52 | | Diluted EPS | -2.66 | -2.94 | -2.52 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
